Astellas Pharma has announced the market launch of Quattrovac subcutaneous injection syringe, the combined vaccine indicated for pertussis, diphtheria, tetanus and poliomyelitis, in Japan.
The vaccine was manufactured by Chemo-Sero-Therapeutic Research Institute at Kaketsuken.
The bulk materials of Kaketsuken's adsorbed purified pertussis diptheria tetanus combined vaccine (DPT vaccine) and the bulk of inactivated poliomyelitis vaccine originated from purified attenuated polio viruses cultured in Vero cells were used in the production of the combined vaccine.
Clinical trials conducted in children with ages not less than three months and not more than 90 months, determined the efficacy and the safety profile of 0.5ml vaccine that was administered subcutaneously.
Trials followed similar vaccination schedule as of the DPT vaccines.
